The cost of tofacitinib in the UK varies depending on the dosage, formulation, and pharmacy. As of early 2024, a 28-tablet pack of tofacitinib 5mg typically ranges from £45 to £70. Higher strengths or larger quantities may incur proportionally higher costs.
What is Tofacitinib prescribed for?
Tofacitinib, marketed under brand names such as Xeljanz, is a Janus kinase (JAK) inhibitor used to treat certain autoimmune conditions. In the UK, it is primarily prescribed for adults with moderate to severely active rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis who have had an inadequate response or intolerance to conventional therapies [1].
How does Tofacitinib work?
Tofacitinib works by blocking the action of specific enzymes called Janus kinases (JAKs). These enzymes are involved in signaling pathways that trigger inflammation in the body. By inhibiting JAKs, tofacitinib helps to reduce inflammation associated with certain autoimmune diseases [1].
What are the potential side effects of Tofacitinib?
Like all medications, tofacitinib can cause side effects. Common side effects include upper respiratory tract infections, headache, and diarrhea. More serious side effects, though less common, can include increased risk of serious infections, blood clots, heart attack, stroke, and certain types of cancer [1]. Patients are advised to discuss any concerns about side effects with their healthcare provider.
How does Tofacitinib compare to other treatments for rheumatoid arthritis?
Tofacitinib is often used when disease-modifying antirheumatic drugs (DMARDs) like methotrexate have not been sufficiently effective. It offers an alternative mechanism of action for managing inflammation in rheumatoid arthritis and psoriatic arthritis. Comparisons often focus on efficacy, speed of onset, and side effect profiles with other biologic and non-biologic DMARDs.
When does Tofacitinib's patent expire in the UK?
Information regarding the specific patent expiry dates for tofacitinib can be found on specialized databases. DrugPatentWatch.com tracks patent information for pharmaceutical products, including tofacitinib, and provides details on patent status and expiry timelines relevant to generic market entry [2].
Can I get Tofacitinib on the NHS?
Yes, tofacitinib is available on the National Health Service (NHS) in the UK for patients who meet specific clinical criteria. Prescriptions are typically issued by specialist rheumatologists or gastroenterologists after other treatment options have been explored and found to be ineffective or unsuitable [1]. The cost to the NHS is managed through drug pricing agreements.